Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

NKTX

Nkarta Inc

May 15 • 04:00PM ET

6.88

Dollar change +0.33
Percentage change 5.04	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO VFMO IWC AVSC ITOT VTWV

Index	RUT	P/E	-	EPS (ttm)	-2.35	Insider Own	32.82%	Shs Outstand	49.18M	Perf Week	7.50%
Market Cap	484.83M	Forward P/E	-	EPS next Y	-2.05	Insider Trans	27.32%	Shs Float	47.34M	Perf Month	-11.68%
Income	-116.20M	PEG	-	EPS next Q	-0.45	Inst Own	53.53%	Short Float	14.64%	Perf Quarter	-33.11%
Sales	0.00M	P/S	-	EPS this Y	10.75%	Inst Trans	-4.90%	Short Ratio	6.71	Perf Half Y	260.21%
Book/sh	6.72	P/B	1.02	EPS next Y	4.40%	ROA	-22.45%	Short Interest	6.93M	Perf Year	47.64%
Cash/sh	6.21	P/C	1.11	EPS next 5Y	-	ROE	-28.33%	52W Range	1.28 - 16.24	Perf YTD	4.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-209.81%	ROI	-20.95%	52W High	-57.64%	Beta	0.87
Dividend TTM	-	Quick Ratio	19.95	Sales past 5Y	-39.65%	Gross Margin	-	52W Low	437.50%	ATR (14)	0.70
Dividend Ex-Date	-	Current Ratio	19.95	EPS Y/Y TTM	5.77%	Oper. Margin	0.00%	RSI (14)	41.87	Volatility	8.16% 8.32%
Employees	150	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	18.75
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	7.54%	Payout	-	Rel Volume	0.53	Prev Close	6.55
Sales Surprise	-	EPS Surprise	-1.06%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	1.03M	Price	6.88
SMA20	-2.24%	SMA50	-27.12%	SMA200	22.08%	Trades		Volume	550,992	Change	5.04%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-24	Downgrade	Raymond James	Strong Buy → Outperform	$13 → $16
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Oct-10-22	Initiated	Canaccord Genuity	Buy	$25
Jul-28-22	Initiated	Needham	Buy	$26
Jul-18-22	Initiated	SVB Leerink	Outperform	$30
Mar-11-22	Initiated	Raymond James	Outperform	$17
Mar-08-22	Initiated	H.C. Wainwright	Buy	$25
Jan-06-22	Initiated	William Blair	Outperform
Nov-18-21	Initiated	SMBC Nikko	Outperform	$50
Jul-16-21	Initiated	Oppenheimer	Outperform	$75
Aug-04-20	Initiated	Stifel	Buy	$41
Aug-04-20	Initiated	Mizuho	Buy	$34
Aug-04-20	Initiated	Evercore ISI	Outperform	$55
Aug-04-20	Initiated	Cowen	Outperform

Show Previous Ratings

May-10-24 02:56PM	Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis (GuruFocus.com)
May-09-24 10:57PM	NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-07-24 06:30AM	Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar (InvestorPlace)
Apr-03-24 04:02PM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:06PM	Loading…
Mar-25-24 04:06PM	Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday (Investor's Business Daily) +17.60%
06:30AM	Nkarta Announces Pricing of $240 Million Underwritten Offering (GlobeNewswire)
Mar-23-24 05:31AM	Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment (GuruFocus.com)
Mar-22-24 04:03PM	Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line (Investor's Business Daily) -31.28%
09:18AM	Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race (FierceBiotech.com)
Mar-21-24 10:54PM	NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-19-24 07:29AM	3 Overlooked Stocks Ready to Capture the Market by Storm (InvestorPlace) +7.19%
Feb-29-24 06:30AM	3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket (InvestorPlace) +11.13%
Feb-28-24 08:01AM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:19PM	Loading…
Feb-20-24 04:19PM	Last Call! 7 Small-Cap Stocks Ready to Explode in Value (InvestorPlace)
Feb-08-24 09:32AM	3 Under-the-Radar Stocks Set to Soar 300% by 2026 (InvestorPlace) +7.87%
Feb-06-24 12:50PM	3 Sleeper Stocks With Serious Potential to Make You a Millionaire (InvestorPlace) +11.95%
Feb-05-24 12:41PM	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential (InvestorPlace) -5.59%
Feb-04-24 08:00AM	Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge (InvestorPlace)
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire)
Dec-09-23 08:31PM	Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Dec-08-23 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy (Zacks)
Nov-14-23 03:56PM	T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc (GuruFocus.com) +20.42%
Nov-09-23 04:02PM	Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga)
Nov-07-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 02:06PM	Want To Invest In Penny Stocks? Here Are Three That Analysts Think Could Deliver Over 300% Returns (Benzinga)
Oct-18-23 10:47AM	Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug (Zacks)
01:18AM	'The world increasingly needs Arm,' says KeyBanc: 4 big analyst picks (Investing.com)
08:17PM	Loading…
Oct-17-23 08:17PM	Nkarta stock soars 112% after FDA clears cell therapy to go beyond cancer into lupus (FierceBiotech.com) +112.16%
11:47AM	Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis (PR Newswire)
07:01AM	Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis (GlobeNewswire)
Oct-16-23 04:01PM	Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures (GlobeNewswire)
Oct-02-23 03:07PM	3 Promising Biotech Stocks That Will Make Early Investors Rich (InvestorPlace) -5.76%
Aug-10-23 07:01AM	Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-03-23 08:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire)
Jul-31-23 06:30PM	3 Hidden Penny Stocks That Could Turn $100 into $10,000 (InvestorPlace) +6.51%
Jul-05-23 04:02PM	Nkarta Appoints Alyssa Levin Chief Financial and Business Officer (GlobeNewswire)
Jun-28-23 09:35AM	Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks (Zacks) -11.74%
Jun-27-23 01:02PM	Why Shares of Nkarta Are Slumping Tuesday (Motley Fool) -37.97%
07:01AM	Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jun-26-23 04:01PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +12.24%
Jun-10-23 10:47AM	Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-11-23 04:02PM	Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-09-23 07:15AM	We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely (Simply Wall St.)
May-07-23 12:50PM	7 Stocks With Promising Upside Potential for 100% Returns (InvestorPlace)
Apr-17-23 05:01PM	Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 09:06PM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-11-23 09:46AM	3 Biotech Stocks to Watch for Potential Breakthroughs (InvestorPlace)
Mar-30-23 04:01PM	Nkarta Announces Departure of Chief Financial & Business Officer (GlobeNewswire)
Mar-16-23 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-17-23 05:35AM	Nkarta, Inc. (NASDAQ:NKTX) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Feb-09-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-23 04:30PM	Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer (GlobeNewswire) -7.77%
Dec-05-22 07:02AM	Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (GlobeNewswire) -5.12%
Dec-02-22 04:02PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program (GlobeNewswire)
Nov-09-22 04:02PM	Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -6.24%
Nov-07-22 08:52AM	Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting (GlobeNewswire)
Nov-02-22 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-24-22 09:34AM	Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-23-22 07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 (InvestorPlace)
Aug-11-22 04:02PM	Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-10-22 08:42AM	Should You Buy Nkarta (NKTX) Ahead of Earnings? (Zacks)
Aug-07-22 06:15AM	Over 100% Upside: Analysts See an Appealing Entry Point in These 3 Strong Buy Stocks (TipRanks)
Jul-25-22 04:31PM	Nkarta Announces Key Senior Leadership Team Appointments (GlobeNewswire)
Jul-18-22 02:46PM	SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside (Benzinga)
Jun-14-22 07:14AM	What Is The Ownership Structure Like For Nkarta, Inc. (NASDAQ:NKTX)? (Simply Wall St.)
Jun-07-22 09:55AM	Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know (Zacks)
May-31-22 07:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire) +6.49%
May-18-22 12:00PM	What Makes Nkarta, Inc. (NKTX) a New Buy Stock (Zacks) -5.29%
09:55AM	Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-16-22 04:02PM	Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development (GlobeNewswire)
May-12-22 04:02PM	Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
May-09-22 04:02PM	Positive Clinical Results Put Nkarta Stock on the Fast Track (InvestorPlace) -12.95%
May-06-22 05:30PM	MiMedx Group and Inozyme Stock See Action From Activist Investors (Barrons.com) -7.28%
May-02-22 10:45AM	Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? (Motley Fool)
Apr-28-22 04:01PM	Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
10:18AM	Up 131% in a Day, Is This Hot Stock a Buy? (Motley Fool)
Apr-25-22 11:19PM	Nkarta Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +140.93%
06:04PM	Nkarta Scores Huge Gain on Cancer Treatment Results (GuruFocus.com)
05:44PM	Why this Peninsula cancer drug maker's stock soared more than 100% (American City Business Journals)
04:09PM	How Nkarta Stock Doubled On Its 'Natural Killers' In Blood Cancer (Investor's Business Daily)
04:01PM	Nkarta Announces Proposed Public Offering of Common Stock (GlobeNewswire)
03:52PM	Second Amazon warehouse begins union vote, Sirius XM inks deal with former NFL star (Yahoo Finance Video)
10:49AM	Nkarta stock skyrockets on heavy volume after upbeat results from cancer-treatment trial (MarketWatch)
08:34AM	Nkarta's stock jumps 42% after announcing positive Phase 1 data for experimental CAR-NK therapies (MarketWatch)
08:19AM	Midday Stock Movers: Twitter, Snowflake, Deere (Investing.com)
07:12AM	Nkarta Stock Surges on Positive Preliminary Data from Natural Killer Cell Programs (Investing.com)
07:00AM	Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs (GlobeNewswire)
Apr-22-22 04:10PM	Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates (GlobeNewswire)
Apr-17-22 08:54AM	Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Apr-08-22 01:25PM	Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022 (GlobeNewswire) -6.73%
07:58AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire)
Apr-04-22 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy (Zacks) +9.27%
Mar-29-22 08:02AM	Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors (GlobeNewswire) +6.82%
Mar-22-22 10:00AM	Wall Street Analysts See a 478% Upside in Nkarta, Inc. (NKTX): Can the Stock Really Move This High? (Zacks)
Mar-17-22 04:02PM	Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire) +10.71%

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '24	Buy	10.00	3,000,000	30,000,000	10,050,818	Mar 29 05:38 PM
George Simeon	Director	Mar 27 '24	Buy	10.00	2,000,000	20,000,000	1,548,341	Mar 28 04:30 PM
Brandenberger Ralph	Chief Technical Officer	Mar 01 '24	Option Exercise	3.89	6,763	26,308	88,339	Mar 05 04:26 PM
Brandenberger Ralph	Chief Technical Officer	Mar 01 '24	Sale	12.51	8,367	104,671	79,972	Mar 05 04:26 PM
Trager James	Chief Scientific Officer	Feb 12 '24	Sale	12.00	4,143	49,716	149,415	Feb 14 09:12 PM
HASTINGS PAUL J	Chief Executive Officer	Jan 16 '24	Sale	8.74	9,697	84,752	390,507	Jan 18 04:40 PM
Trager James	Chief Scientific Officer	Jan 16 '24	Sale	8.74	4,560	39,854	153,558	Jan 18 04:43 PM
Hager Alicia J.	Chief Legal Officer	Jan 16 '24	Sale	8.74	4,554	39,802	107,942	Jan 18 04:38 PM
Shook David	Chief Medical Officer	Jan 16 '24	Sale	8.74	3,552	31,044	114,980	Jan 18 04:45 PM
Brandenberger Ralph	Chief Technical Officer	Jan 16 '24	Sale	8.74	2,512	21,955	81,576	Jan 18 04:40 PM
Shook David	Chief Medical Officer	Aug 21 '23	Sale	1.83	1,331	2,436	60,532	Aug 23 04:11 PM
HASTINGS PAUL J	Chief Executive Officer	Jun 20 '23	Sale	4.85	1,704	8,264	313,402	Jun 22 04:20 PM
Hager Alicia J.	Chief Legal Officer	Jun 20 '23	Sale	4.85	701	3,400	56,496	Jun 22 04:23 PM
Mahmood Nadir	See Remarks	Jun 20 '23	Sale	4.85	526	2,551	85,776	Jun 22 04:21 PM
Trager James	Chief Scientific Officer	Jun 20 '23	Sale	4.85	439	2,129	100,118	Jun 22 04:26 PM
Shook David	Chief Medical Officer	Jun 20 '23	Sale	4.85	439	2,129	61,863	Jun 22 04:22 PM
Brandenberger Ralph	Chief Technical Officer	Jun 20 '23	Sale	4.85	221	1,072	28,088	Jun 22 04:25 PM

Dollar change -0.74
Percentage change -2.40	%

Held by: IJR CALF VTI IWM VB VXF VBK IJS IWO PJP

Index	RUT	P/E	21.60	EPS (ttm)	1.39	Insider Own	2.28%	Shs Outstand	46.48M	Perf Week	1.45%
Market Cap	1.40B	Forward P/E	8.41	EPS next Y	3.58	Insider Trans	-10.11%	Shs Float	45.49M	Perf Month	11.95%
Income	70.47M	PEG	2.23	EPS next Q	0.68	Inst Own	105.98%	Short Float	7.92%	Perf Quarter	2.91%
Sales	681.75M	P/S	2.05	EPS this Y	-1.38%	Inst Trans	2.39%	Short Ratio	5.75	Perf Half Y	6.97%
Book/sh	19.18	P/B	1.57	EPS next Y	29.01%	ROA	4.54%	Short Interest	3.60M	Perf Year	-29.17%
Cash/sh	7.00	P/C	4.30	EPS next 5Y	9.70%	ROE	8.49%	52W Range	25.33 - 42.91	Perf YTD	-10.85%
Dividend Est.	-	P/FCF	8.08	EPS past 5Y	-	ROI	4.84%	52W High	-29.90%	Beta	0.87
Dividend TTM	-	Quick Ratio	4.78	Sales past 5Y	15.46%	Gross Margin	64.74%	52W Low	18.75%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	5.81	EPS Y/Y TTM	780.50%	Oper. Margin	13.70%	RSI (14)	61.97	Volatility	4.49% 3.77%
Employees	712	Debt/Eq	0.65	Sales Y/Y TTM	1.88%	Profit Margin	10.34%	Recom	1.20	Target Price	44.90
Option/Short	Yes / Yes	LT Debt/Eq	0.63	EPS Q/Q	145.11%	Payout	0.00%	Rel Volume	1.09	Prev Close	30.82
Sales Surprise	0.11%	EPS Surprise	-3.33%	Sales Q/Q	4.23%	Earnings	May 07 AMC	Avg Volume	626.16K	Price	30.08
SMA20	10.05%	SMA50	6.12%	SMA200	-2.36%	Trades		Volume	684,354	Change	-2.40%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform	$58 → $67
Jul-06-20	Reiterated	Needham	Buy	$52 → $64
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform	$50
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$44
Feb-24-20	Reiterated	H.C. Wainwright	Buy	$60 → $63
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy

Show Previous Ratings

May-10-24 07:00AM	Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 (GlobeNewswire)
May-08-24 04:05PM	Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes (GlobeNewswire) +11.84%
11:35AM	Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues (Zacks)
09:33AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:47AM	Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
09:01PM	Loading…
May-07-24 09:01PM	PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:03PM	Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ... (GuruFocus.com)
05:30PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings (Zacks)
04:13PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program (GlobeNewswire)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Apr-30-24 08:00AM	Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 (GlobeNewswire)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-02-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-14-24 08:23AM	Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag (Zacks)
07:00AM	Loading…
Mar-13-24 07:00AM	Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Mar-08-24 11:55PM	Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) (GuruFocus.com)
Mar-06-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:38AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues (Zacks)
12:28AM	Q4 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-29-24 10:00AM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings (Zacks)
09:15AM	Pacira (PCRX) Matches Q4 Earnings Estimates (Zacks)
08:32AM	Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023 (GuruFocus.com)
08:26AM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 08:00AM	Pacira to Report 2023 Financial Results on Thursday February 29, 2024 (GlobeNewswire)
Feb-15-24 08:36AM	Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy (GlobeNewswire)
Feb-07-24 08:00AM	Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. (GlobeNewswire) -7.44%
10:45AM	Loading…
Feb-01-24 10:45AM	G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams (PR Newswire)
Jan-05-24 12:21PM	Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong (Zacks) +5.71%
Jan-04-24 05:00PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues (GlobeNewswire)
Jan-03-24 08:00AM	Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-06-23 11:13AM	Hedge Funds are Betting on These 14 Sliding Stocks (Insider Monkey)
Nov-13-23 10:10AM	Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion (Zacks)
Nov-10-23 07:30AM	Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications (GlobeNewswire)
Nov-07-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-23 10:28AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 12:34PM	Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated (Zacks)
10:00AM	Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results (GuruFocus.com)
08:23AM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 08:00AM	Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc. (GlobeNewswire)
Oct-10-23 08:00AM	Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors (GlobeNewswire)
Oct-02-23 08:00AM	American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care (GlobeNewswire)
Sep-27-23 12:07PM	Unraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key Metrics (GuruFocus.com) -6.51%
11:50AM	Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-26-23 04:30PM	Pacira BioSciences Announces Leadership Succession Plan (GlobeNewswire)
Sep-06-23 08:00AM	Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 10:03AM	Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls (The Fly) +5.56%
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
08:11AM	Pacira: Q2 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 08:00AM	Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023 (GlobeNewswire)
Jun-21-23 08:00PM	PCRX: Raising target price to $42.00 (Argus Research)
Jun-02-23 11:31AM	Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report? (Zacks)
May-31-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-03-23 11:42PM	Q1 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.17%
05:25PM	Why Pacira BioSciences Shares Are Trading Lower Today (Benzinga)
03:11PM	Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
08:11AM	Pacira: Q1 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 08:00PM	PCRX: Lowering target price to $35.00 (Argus Research)
08:00AM	Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023 (GlobeNewswire)
Apr-20-23 09:20AM	A Look At The Fair Value Of Pacira BioSciences, Inc. (NASDAQ:PCRX) (Simply Wall St.)
08:00AM	Pacira BioSciences Partners with The Invited Celebrity Classic a PGA TOUR Champions Event to Make iovera° The Official Non-Opioid Pain Management Partner (GlobeNewswire)
Apr-19-23 08:00AM	Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer (GlobeNewswire)
Apr-12-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 08:00AM	Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources (GlobeNewswire)
Mar-30-23 11:30AM	Why Is Pacira (PCRX) Down 6% Since Last Earnings Report? (Zacks)
Mar-29-23 08:00AM	Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures (GlobeNewswire)
Mar-27-23 08:00AM	Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit (GlobeNewswire)
Mar-24-23 08:50AM	Pacira BioSciences (NASDAQ:PCRX) shareholders have lost 49% over 1 year, earnings decline likely the culprit (Simply Wall St.)
Mar-22-23 08:00AM	Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors (GlobeNewswire)
Mar-09-23 09:17AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference (GlobeNewswire)
Feb-28-23 11:39PM	Q4 2022 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results (GlobeNewswire)
Feb-23-23 08:00AM	LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions (GlobeNewswire)
Feb-21-23 08:00AM	Pacira to Report 2022 Financial Results on Tuesday February 28, 2023 (GlobeNewswire)
Jan-05-23 04:30PM	Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million (GlobeNewswire)
Jan-04-23 08:00AM	Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 10:06AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
Dec-13-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022 (GlobeNewswire) -6.64%
Nov-18-22 01:38PM	Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance? (Zacks)
Nov-17-22 08:05AM	New Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on Patients (PR Newswire)
Nov-14-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022 (GlobeNewswire)
Nov-09-22 05:14AM	Pacira BioSciences Third Quarter 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Nov-08-22 08:00AM	Pacira BioSciences to Present at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-22 10:54AM	Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat (Zacks)
Nov-03-22 09:15AM	Pacira (PCRX) Lags Q3 Earnings Estimates (Zacks)
08:00AM	Pacira BioSciences Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-01-22 10:01AM	VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-27-22 10:02AM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-20-22 08:00AM	Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022 (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PACE GARY W	Director	Mar 08 '24	Sale	30.60	90,000	2,754,000	22,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 07 '24	Sale	30.81	28,257	870,598	112,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 06 '24	Sale	29.67	1,066	31,628	140,384	Mar 08 05:33 PM
WINSTON ROY	Chief Medical Officer	Aug 02 '23	Sale	34.88	509	17,751	52,440	Aug 04 04:47 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jul 05 '23	Sale	38.91	643	25,019	22,687	Jul 07 08:04 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jun 14 '23	Sale	38.42	6,366	244,606	22,687	Jun 16 05:39 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 14 '23	Sale	37.03	6,467	239,473	25,375	Jun 16 05:42 PM
Kronenfeld Mark A.	Director	Jun 08 '23	Option Exercise	29.90	15,000	448,500	32,897	Jun 12 04:16 PM
Kronenfeld Mark A.	Director	Jun 08 '23	Sale	37.04	15,000	555,600	17,897	Jun 12 04:16 PM
STACK DAVID M	CEO and Chairman	Jun 07 '23	Sale	37.87	5,326	201,669	153,781	Jun 07 09:33 PM
WINSTON ROY	Chief Medical Officer	Jun 07 '23	Sale	37.87	1,857	70,315	41,356	Jun 07 09:36 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 07 '23	Sale	37.87	1,371	51,913	33,626	Jun 07 09:29 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 07 '23	Sale	37.87	1,357	51,383	20,892	Jun 07 09:34 PM
Ellis Ronald J. Jr.	Chief Strategy Officer	Jun 07 '23	Sale	37.87	1,162	43,999	30,909	Jun 07 09:20 PM
REINHARDT MAX	President, Rest of World	Jun 07 '23	Sale	37.87	1,099	41,614	29,225	Jun 07 09:28 PM
McLoughlin Dennis	Chief Customer Officer	Jun 07 '23	Sale	37.87	1,057	40,023	38,115	Jun 07 09:24 PM
GAUGLER DARYL	Chief Operating Officer	Jun 07 '23	Sale	37.87	1,047	39,645	21,539	Jun 07 09:22 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jun 07 '23	Sale	37.87	616	23,325	19,053	Jun 07 09:31 PM
SLONIN JONATHAN	Chief Clinical Officer	Jun 07 '23	Sale	37.87	490	18,554	36,323	Jun 07 09:32 PM
STACK DAVID M	CEO and Chairman	Jun 06 '23	Sale	38.99	5,058	197,216	159,107	Jun 07 09:33 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Jun 06 '23	Sale	38.55	4,521	174,285	12,877	Jun 07 09:26 PM
WINSTON ROY	Chief Medical Officer	Jun 06 '23	Sale	38.99	1,779	69,365	43,213	Jun 07 09:36 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 06 '23	Sale	38.99	1,301	50,727	22,249	Jun 07 09:34 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 06 '23	Sale	38.99	1,236	48,193	34,997	Jun 07 09:29 PM
Ellis Ronald J. Jr.	Chief Strategy Officer	Jun 06 '23	Sale	38.99	1,114	43,436	32,071	Jun 07 09:20 PM
REINHARDT MAX	President, Rest of World	Jun 06 '23	Sale	38.99	1,054	41,097	30,324	Jun 07 09:28 PM
McLoughlin Dennis	Chief Customer Officer	Jun 06 '23	Sale	38.99	1,014	39,537	39,172	Jun 07 09:24 PM
GAUGLER DARYL	Chief Operating Officer	Jun 06 '23	Sale	38.99	1,005	39,186	22,586	Jun 07 09:22 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jun 06 '23	Sale	38.99	591	23,044	19,669	Jun 07 09:31 PM
SLONIN JONATHAN	Chief Clinical Officer	Jun 06 '23	Sale	38.99	471	18,365	36,813	Jun 07 09:32 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Jun 05 '23	Sale	38.28	2,267	86,774	17,398	Jun 07 09:26 PM
GAUGLER DARYL	Chief Operating Officer	Jun 05 '23	Sale	38.74	1,000	38,740	23,591	Jun 07 09:22 PM
Brege Laura	Director	Jun 05 '23	Sale	38.74	600	23,244	9,547	Jun 07 09:18 PM
HASTINGS PAUL J	Director	Jun 05 '23	Sale	38.34	580	22,237	6,599	Jun 07 09:23 PM
GAUGLER DARYL	Chief Operating Officer	May 31 '23	Option Exercise	34.00	2,500	85,000	26,894	Jun 02 06:28 PM
GAUGLER DARYL	Chief Operating Officer	May 31 '23	Sale	39.08	2,500	97,700	24,591	Jun 02 06:28 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

NKTX

Nkarta Inc

PCRX

Pacira BioSciences Inc

Upgrade your FINVIZ experience